The Phase I trial will evaluate the safety and efficacy of CB3304 (noscapine) administered daily to patients with relapsed or refractory multiple myeloma. The trial will be conducted at Weill Cornell Medical College and Columbia Presbyterian Medical Center.
Alan Auerbach, CEO and president of Cougar Biotechnology, said: “We are pleased to be able to move CB3304 into clinical development. This represents the second drug in Cougar’s pipeline to advance into clinical trials and also represents a key corporate objective for the Company this year.”